Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06003426 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
A Phase 3 study of Idiopathic Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 1,255
- Enrollment target
- 20
- Study locations
NCT06003426: Active Phase 3 study of Idiopathic Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb.
NCT06003426 is a Phase 3 study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 1,255 participants, above the 727-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06003426, a Phase 3 study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,255 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Primary Outcome
Cohort 1
Conditions Studied
Interventions
- DRUG BMS-986278
- DRUG BMS-986278 Placebo
Study Locations (20)
California
- Local Institution - 0396 - La Jolla
- Local Institution - 0193 - Los Angeles
- Local Institution - 0398 - Los Angeles
- Local Institution - 0389 - Orange
- Local Institution - 0405 - Sacramento
- Local Institution - 0185 - San Francisco
- Local Institution - 0186 - Stanford
Florida
- Local Institution - 0101 - Brandon
- Local Institution - 0436 - Clearwater
- Local Institution - 0425 - DeBary
- Local Institution - 0079 - Gainesville
- Local Institution - 0352 - Hialeah
- Local Institution - 0370 - Kissimmee
Colorado
- Local Institution - 0363 - Aurora
- Local Institution - 0194 - Denver
Alabama
- Local Institution - 0189 - Birmingham
Arizona
- Local Institution - 0361 - Phoenix
Connecticut
- Local Institution - 0175 - New Haven
Delaware
- Local Institution - 0151 - Newark
District of Columbia
- Local Institution - 0367 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,255 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2026-10-26 |
| Phase | Phase 3 |
What the registry record for NCT06003426 still lists
NCT06003426 is an interventional study that assigns participants to a tested intervention. Its 1,255 participants enrollment target places it among the larger protocols in the corpus, above the 727-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (73% higher).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986278 is the first listed.
NCT06003426 names 20 study sites across 8 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06003426 about?
NCT06003426 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis". The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
What is the current status of trial NCT06003426?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,255 participants. The study started on 2023-09-14. Estimated completion is 2026-10-26.
What conditions does trial NCT06003426 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT06003426?
The interventions under investigation include: BMS-986278 (DRUG), BMS-986278 Placebo (DRUG).
Who is sponsoring clinical trial NCT06003426?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06003426 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06003426's enrollment target sits among peer trials
1,255 5th of 51 higher than 47 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
RECRUITING · Phase 3
-
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
COMPLETED · Phase 3
-
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
COMPLETED · Phase 3
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI